Marshall Wace, LLP Rubius Therapeutics, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $20,546 - $155,527	-26,008 Reduced 5.76%	425,497 $362,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $1.92 Million - $4.7 Million	451,505 New	451,505 $2.49 Million
Q1 2020 May 15, 2020	SELL	$3.74 - $9.84 $43,686 - $114,941	-11,681 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.23 - $14.12 $84,453 - $164,935	11,681 New	11,681 $111,000
Q2 2019 Aug 14, 2019	SELL	$13.5 - $19.94 $1.07 Million - $1.59 Million	-79,523 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$13.27 - $18.51 $1.06 Million - $1.47 Million	79,523 New	79,523 $1.44 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.